Delisting risk
OSRH · NASDAQ · Biotechnology

OSR (OSRH)

Combines cancer immunotherapies and regenerative biologics with Korean neurovascular-device distribution.

$0.1165
At close0.00 (0.00%)

Something off on this page? Send us feedback.

Next report
Dec 2, 2026
estimated · in 90 days
EPS estimate
−$0.27
Revenue estimate
$780.0K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
Reported−$0.16−$1.04$0.02−$0.10−$2.02−$0.09−$0.02Pending
Estimate−$0.12−$0.10−$0.29−$0.28−$0.27
Surprise+16.7%−1,920.0%+69.0%+92.9%

RevenueReportedEstimate

Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
Reported−$2.4M$761.3K$1.1M$627.7K$381.3K$484.1K$315.7KPending
Estimate$760.0K$760.0K$780.0K$780.0K$780.0K
Surprise−17.4%−49.8%−37.9%−59.5%

History

DateEstimateReportedSurprise
Dec 2026−$0.27
Aug 2026−$0.28−$0.02+92.9%
May 2026−$0.29−$0.09+69.0%
Mar 2026−$0.10−$2.02−1,920.0%
Nov 2025−$0.12−$0.10+16.7%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Apr 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Sep 2023
Aug 2023
May 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2, 2026−$0.27$780.0K
Aug 14, 2026−$0.28−$0.02+92.9%$780.0K$315.7K−59.5%+11.7%
May 13, 2026−$0.29−$0.09+69.0%$780.0K$484.1K−37.9%−2.7%
Mar 31, 2026−$0.10−$2.02−1,920.0%$760.0K$381.3K−49.8%−2.7%
Nov 12, 2025−$0.12−$0.10+16.7%$760.0K$627.7K−17.4%−4.2%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 14, 2025
May 20, 2025
Apr 22, 2025
Nov 15, 2024
Aug 20, 2024
May 16, 2024
Apr 18, 2024
Sep 30, 2023
Aug 15, 2023
May 23, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021